Brii Biosciences Limited (SEHK: 2137)
Health Care · Biotechnology · CN
HK$1.02
+3.05% today · -48.7% 1Y
Brii Biosciences Limited (SEHK: 2137) operates in the Biotechnology industry within the Health Care sector. The company is valued at $93.45M and employs 75 people.
Over the last twelve months the share price has lost 48.7%, trading between 0.90 and 2.34.
Tweenvest scores Brii Biosciences Limited across four factors: quality 33/100, value 44/100. Its strongest factor is value.
2137 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $93.45M
- Revenue (TTM)
- $8.44M
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- 1.20
- 52-week high
- HK$2.34
- 52-week low
- HK$0.90
- Avg volume (3M)
- —
- Shares outstanding
- 721.81M
- Employees
- 75
- Next earnings
- —
About Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
- ISIN
- KYG1645A1094
- Founded
- 2017
- Listed since
- Jul 13, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.